The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

Table 2

Patient characteristics at diagnosis according to the type of novel agents in the first-line therapy.

Parameters	Total (%)	Bortezomib-based group (%)	Thalidomide-based group (%)	value
Patient ()	1016	709	307
Male	59.7%	60.1%	59.0%	0.394
Age >60 years	44.2%	40.3%	53.1%	0.0001
Hemoglobin <10 g/dL	61.5%	60.2%	64.8%	0.253
Creatinine ≥2 mg/mL	19.2%	20.3%	16.4%	0.183
BM plasma cell percentage ≥40%	36.3%	38.8%	30.2%	0.012
Platelet counts <130 10^9/L	30.9%	31.7%	29.2%	0.454
PN	12.3%	10.7%	15.4%	0.063
LDH ≥245 U/L	14.6%	14.9%	13.8%	0.689
Albumin (<35 g/L)	47.4%	43.6%	56.1%	0.0001
β2-MG (≥3.5 mg/L)	55.3%	56.1%	53.4%	0.028
DS stage				0.483
I	2.5%	2.2%	3.6%
II	9.5%	9.3%	10.1%
III	88.0%	88.5%	86.3%
ISS stage				0.343
I	22.7%	24.0%	26.4%
II	33.6%	33.3%	34.2%
III	43.7%	42.7%	45.9%
Myeloma type				0.050
IgG	44.1%	42.6%	47.6%
IgA	22.2%	23.6%	19.2%
IgD	7.4%	8.5%	4.9%
κ light chain	12.0%	12.1%	11.7%
λ light chain	11.1%	11.0%	11.4%
others	3.2%	2.2%	5.2%
Regimens of the first-line therapy		PAD/VD/BCD/V-DECP	TAD/TD/MPT/CTP/T-DECP
≥PR to the first-line therapy	80%	84.1%	68.8%	0.0001

BM: bone marrow, PN: peripheral neuropathy, LDH: lactate dehydrogenase, DS stage: Durie-Salmon stage, ISS: International Staging System, OS: overall survival, PAD: Bortezomib (Velcade), Adriamycin, and Dexamethasone, VD: Bortezomib (Velcade) and Dexamethasone, BCD: Bortezomib (Velcade), Cyclophosphamide, and Dexamethasone, V-DECP: Bortezomib Cisplatin, Etoposide, Cyclophosphamide, and Dexamethasone; TD: Thalidomide and Dexamethasone, TAD: Thalidomide, Adriamycin, and Dexamethasone, MPT: Melphalan, Prednisone, and Thalidomide, T-DECP: Thalidomide, Cisplatin, Etoposide, Cyclophosphamide, and Dexamethasone; CTP: Cyclophosphamide, Thalidomide, and Dexamethasone, and PR: partial response.